Blog

Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Open filters
Search
Tags
Author
Alison Sathe
Anders Vinther
Barbara W. Unger
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Mark Agostino
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

On-Demand Webinar: Insights on API Inspection Deficiencies

No items found.

Peter Baker’s Roadmap to Quality Intelligence

Data integirty
Inspections
Pharma
Quality
Quality Intelligence
Conference Spotlight

A Deep Dive into Cell and Gene Therapy Regulatory Considerations: Part Two

Cell and Gene
FDA
GMP
Inspections
Pharma

On-Demand Webinar: Legal Considerations when Interacting with the FDA

No items found.
Trends

Redica Responds: What are Common Laboratory Inspection Findings?

483
Inspections
laboratory
Quality
Conference Spotlight

A Deep Dive into Cell and Gene Therapy Regulatory Considerations: Part One

Cell and Gene
CGT
Quality
Enforcement

Internal Audit Reports: Can the FDA Take a Peek?

FDA
GMP
Internal Audits
Pharma
Quality

Audience Q&A: From Data Integrity and Quality Culture Webinar

No items found.
Conference Spotlight

Is Raw FDA Data Skewing Your Analyses?

Drug recalls
GMP
Pharma
Quality
quality systems

On-Demand Webinar: Quality Intelligence: from Information to Knowledge

No items found.

Beyond Data Integrity: Ulrich Köllisch on Building a Culture for Tomorrow’s High-End Data Tools

483
Data Integrity
GMP
Quality
Conference Spotlight

Should ICH Tackle Standard Development for CGT Products?

483
GMP
ICH
ISPE Annual Meeting
Pharma

What Are Inferred CFR Codes?

CFR
citations
Dupont
FDA
Form 483

On-Demand Webinar | Comparing Inspection Observations between FDA and Health Canada

No items found.

Does Your Lab Instrumentation Adhere to Data Integrity Requirements?

analytical instruments
Bob McDowall
Data Ingegrity
Quality
Conference Spotlight

FDA on the Evolution of Biologics Inspections: Part III

Biologics
BLAs
FDA
FDA inspection
remote inspection

The “O” in ALCOA

No items found.

How “Inevitable” Data Integrity Issues Cause Havoc: Part II

No items found.